Over the weekend, the Orange King claimed that the USD was too strong because China was keeping the Yuan too weak, adding that our "companies can’t compete with them now because our currency is too strong, and it’s killing us.” U.S. stocks slump as Trump’s dollar comment rattles investors - MarketWatch
Trump has claimed repeatedly that China was manipulating it currency lower, an assertion that demonstrates a profound level of ignorance and an unwillingness to change an opinion based on accurate information rather than his own reality creations.
China is spending billions in reserves to keep its overvalued currency from declining faster-the exact opposite of keeping the Yuan too weak. When China allowed the Yuan to decline at a fast rate during the 2015 summer, the world's stock markets went into a tailspin.
One problem leading to the Yuan's weakness is capital outflows that China has been attempting to curb. China’s Foreign Reserves Drop Most in 10 Months as Yuan Slumps - Bloomberg
Chinese foreign reserves slide as yuan falls - Business Insider ("The government is also using up foreign reserves to stop the yuan from falling faster than it is.")
How We Know China's Central Bankers Are Worried About the Yuan-Fortune.com ("Chinese officials were working hard to support the yuan from crashing even further and inciting panic about the country's financial position.")
"Currency Wars Are the Big Threat to Global Trade" - Barron's
"Sorry, Trump, but Chinese Currency Is Actually Way Overvalued" - Barron's
"Trump Is Still Wrong About the Yuan" - Barron's
"Currency Reserves Drop As China Manipulates Yuan Up In Value": Forbes
China burns through nearly $70 billion trying to prop up its currency - Dec. 7, 2016: CNBC
+++++++++++
Trump: 'I don’t like tweeting’
The only reason why Trump tweets is to provide truth to those who pay attention to the false propaganda and fake news spewed from the mainstream media particularly from the NYT and the Washington Post. For example, there are still a few souls who do not recognize that the "concept of global warming was created by and for the Chinese in order to make U.S. manufacturing non-competitive." Yes, Donald Trump did call climate change a Chinese hoax It is shocking, unbelievable really and truly, that the mainstream media has not yet discovered that self-evident truth.
I See The Light Now
or Hank Williams is almost on point: Hank Williams- I saw The Light - YouTube
or maybe the Infamous Stringdusters' Version of Bob Dylan's 1962 song Don't Think Twice It's Alright - YouTube
+++
I had a scheduled rollover yesterday of a 4 week treasury bill that was auctioned at a .52% rate: Results.pdf
1. Small Cap Biotech Lottery Ticket Basket Strategy
Yesterday was another bad day for pharmaceutical stocks as the Orange King, not to be confused with the Sun King despite many similarities, expressed his oft repeated opinion that Medicare and Medicaid need to negotiate drug prices directly with the drug companies, adding that this approach was part of his "insurance for everybody" (details to be supplied at a later time) Trump vows ‘insurance for everybody’ in Obamacare replacement plan - The Washington Post; Trump’s Strategy for Cutting Drug Prices Is DOA - Bloomberg View
So, I looked around for another small cap biotech lottery ticket to buy.
It may be possible for Trump to brow beat and bully enough GOP representatives too support a federal government price control plan relying on mostly Democrats to pass the legislation. I will believe that when I see it happen.
Trump has claimed repeatedly that China was manipulating it currency lower, an assertion that demonstrates a profound level of ignorance and an unwillingness to change an opinion based on accurate information rather than his own reality creations.
China is spending billions in reserves to keep its overvalued currency from declining faster-the exact opposite of keeping the Yuan too weak. When China allowed the Yuan to decline at a fast rate during the 2015 summer, the world's stock markets went into a tailspin.
One problem leading to the Yuan's weakness is capital outflows that China has been attempting to curb. China’s Foreign Reserves Drop Most in 10 Months as Yuan Slumps - Bloomberg
Chinese foreign reserves slide as yuan falls - Business Insider ("The government is also using up foreign reserves to stop the yuan from falling faster than it is.")
How We Know China's Central Bankers Are Worried About the Yuan-Fortune.com ("Chinese officials were working hard to support the yuan from crashing even further and inciting panic about the country's financial position.")
"Currency Wars Are the Big Threat to Global Trade" - Barron's
"Sorry, Trump, but Chinese Currency Is Actually Way Overvalued" - Barron's
"Trump Is Still Wrong About the Yuan" - Barron's
"Currency Reserves Drop As China Manipulates Yuan Up In Value": Forbes
China burns through nearly $70 billion trying to prop up its currency - Dec. 7, 2016: CNBC
+++++++++++
Trump: 'I don’t like tweeting’
The only reason why Trump tweets is to provide truth to those who pay attention to the false propaganda and fake news spewed from the mainstream media particularly from the NYT and the Washington Post. For example, there are still a few souls who do not recognize that the "concept of global warming was created by and for the Chinese in order to make U.S. manufacturing non-competitive." Yes, Donald Trump did call climate change a Chinese hoax It is shocking, unbelievable really and truly, that the mainstream media has not yet discovered that self-evident truth.
I See The Light Now
or Hank Williams is almost on point: Hank Williams- I saw The Light - YouTube
or maybe the Infamous Stringdusters' Version of Bob Dylan's 1962 song Don't Think Twice It's Alright - YouTube
+++
I had a scheduled rollover yesterday of a 4 week treasury bill that was auctioned at a .52% rate: Results.pdf
1. Small Cap Biotech Lottery Ticket Basket Strategy
Yesterday was another bad day for pharmaceutical stocks as the Orange King, not to be confused with the Sun King despite many similarities, expressed his oft repeated opinion that Medicare and Medicaid need to negotiate drug prices directly with the drug companies, adding that this approach was part of his "insurance for everybody" (details to be supplied at a later time) Trump vows ‘insurance for everybody’ in Obamacare replacement plan - The Washington Post; Trump’s Strategy for Cutting Drug Prices Is DOA - Bloomberg View
So, I looked around for another small cap biotech lottery ticket to buy.
It may be possible for Trump to brow beat and bully enough GOP representatives too support a federal government price control plan relying on mostly Democrats to pass the legislation. I will believe that when I see it happen.
If I had to guess, OMER is more likely to produce a winner than Celldex (CLDX) which is the last small cap biotech that I discussed here.
I will admit to ignorance about the science.
Importantly, OMER does have an approved product, OMIDRIA, that is currently being sold.
11/10/16 Motley Fool Article: Why Omeros Corporation Is Soaring 17.7% Today
The company does have several current shots on goal:
Omeros Pipeline
The furthest along is OMS721 for atypical hemolytic uremic syndrome. I would have to google those words to have a clue.
Atypical Hemolytic Uremic Syndrome - NORD (National Organization for Rare Disorders)
Symptoms and causes - IgA nephropathy (Berger's disease) - Mayo Clinic
I do not bust any brain cells researching small cap biotech companies, recognizing that any opinion formed even after extensive research would have either a zero value or more likely a negative one. I am basically throwing a lot of names against the wall and hopefully one or two will become 10+ baggers.
I do need to generate at least a lay person's interest in the science before buying and some kind of positive "gut" reaction to the possibilities. To reach that point, I need to spend about an hour reading recent press releases, the last earnings press release, and discussions about the pipeline. I will also do a cursory review the last Annual Report and will quickly look at the history of stock offerings.
Omeros - 2016 Press Releases
Omeros Corporation Reports Third Quarter 2016 Financial Results ("company reported in October 2016 positive data (p = 0.017) from its Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, including IgA nephropathy and membranous nephropathy, none of which currently have an approved treatment and all of which frequently lead to end-stage renal disease and dialysis. In this trial, OMS721 significantly improved key endpoints of renal function and patients achieved partial remission with 12 weeks of dosing. ... reported in August 2016 that it received scientific advice from the European Medicines Agency (EMA) directed to its OMS721 Phase 3 program for the treatment of aHUS. Based on this EMA advice, the company plans to run the same, single-arm Phase 3 clinical trial to support OMS721 marketing approval applications in both the U.S. and in the EU for the treatment of aHUS.")
Q3 2016 Results - Earnings Call Transcript | Seeking Alpha
2. Healthcare Basket Strategy: Sold 50 SNY
Atypical Hemolytic Uremic Syndrome - NORD (National Organization for Rare Disorders)
Symptoms and causes - IgA nephropathy (Berger's disease) - Mayo Clinic
I do not bust any brain cells researching small cap biotech companies, recognizing that any opinion formed even after extensive research would have either a zero value or more likely a negative one. I am basically throwing a lot of names against the wall and hopefully one or two will become 10+ baggers.
I do need to generate at least a lay person's interest in the science before buying and some kind of positive "gut" reaction to the possibilities. To reach that point, I need to spend about an hour reading recent press releases, the last earnings press release, and discussions about the pipeline. I will also do a cursory review the last Annual Report and will quickly look at the history of stock offerings.
Omeros - 2016 Press Releases
Omeros Corporation Reports Third Quarter 2016 Financial Results ("company reported in October 2016 positive data (p = 0.017) from its Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, including IgA nephropathy and membranous nephropathy, none of which currently have an approved treatment and all of which frequently lead to end-stage renal disease and dialysis. In this trial, OMS721 significantly improved key endpoints of renal function and patients achieved partial remission with 12 weeks of dosing. ... reported in August 2016 that it received scientific advice from the European Medicines Agency (EMA) directed to its OMS721 Phase 3 program for the treatment of aHUS. Based on this EMA advice, the company plans to run the same, single-arm Phase 3 clinical trial to support OMS721 marketing approval applications in both the U.S. and in the EU for the treatment of aHUS.")
Q3 2016 Results - Earnings Call Transcript | Seeking Alpha
2. Healthcare Basket Strategy: Sold 50 SNY
SNY Profit Snapshot: Barely Worth the Effort
 |
| 2017 SNY 50 Shares +$130.36 |
I discussed this purchase here: 1. Bought Back 50 SNY at $38.86: Update For Healthcare Basket Strategy As Of 2/25/16 - South Gent | Seeking Alpha
For this lot, I did receive the 2016 annual dividend payment. Fidelity does take the necessary steps to secure the applicable 15% dividend rate mandated under Article 10 of the U.S-France tax treaty.
The $2.25 fee is paid to the ADR custodian and is withheld before the dividend payment arrives at my broker.
Adding the one annual dividend adjusted for the ADR fee to my $130.36 profit, the total dollar return is $211.27 or 10.85% with about an 11 month holding period.
Historically, that is about as good as I have been able to do with this stock, so I harvested my profit and will look for an opportunity to buy back a 50 share lot prior to the next annual ex dividend date.
I have nothing new to add to my prior SNY discussions.
3. Intermediate Term Bond Basket Ladder Strategy:
For this lot, I did receive the 2016 annual dividend payment. Fidelity does take the necessary steps to secure the applicable 15% dividend rate mandated under Article 10 of the U.S-France tax treaty.
The $2.25 fee is paid to the ADR custodian and is withheld before the dividend payment arrives at my broker.
Adding the one annual dividend adjusted for the ADR fee to my $130.36 profit, the total dollar return is $211.27 or 10.85% with about an 11 month holding period.
Historically, that is about as good as I have been able to do with this stock, so I harvested my profit and will look for an opportunity to buy back a 50 share lot prior to the next annual ex dividend date.
I have nothing new to add to my prior SNY discussions.
3. Intermediate Term Bond Basket Ladder Strategy:
Bought 2 AT & T 3% Senior Unsecured Bonds Maturing on 2/15/22
FINRA Page: Bond Detail (bond prospectus linked at Finra Page)
| Moody's Rating | Baa1 (08/29/2016) |
| Standard & Poor's Rating | BBB+ (02/02/2015) |
| Fitch Rating | A- (10/24/2016) |
YTM at Total Cost = 3.042% (bought at 99.701; 99.801 with $2 commission)
AT & T SEC Filings
2016 Third Quarter Earnings Release
AT & T SEC Filings
2016 Third Quarter Earnings Release
4. SOLD 100 PWR.PR.T AT C$21.41
QUOTE: Power Financial Corp. 4.2% Pfd. Series T Stock (PWF.PR.T:TOR)
PWFPRT has a 4.25% coupon until it resets 1/31/19 at a 2.37% spread to the five year Canadian bond for a five year period. Par value is C$25. The break point for the five year bond would be 1.88% on the reset date. If the five year bond is higher than 1.88% on the reset date, then the reset coupon will exceed the current fixed rate one.
Profit Snapshot: +C$190.5
I bought this 100 share lot in two fifty lots: at C$19.47 on 10/03/16 and at $C19.52 on 12/8/16.
I discussed selling a 50 share lot at C$20.97 here.
This security was ex dividend for its quarterly distribution on 1/7/16.
I am moving some CADs into purchases of gold mining stocks. I discussed my reasons in the last post. Item # 1
I have been taking profits on my Canadian reset equity preferred positions.
I classify the Canadian reset preferred stocks as part of the equity preferred floating rate securities, and trade snapshots can be found in that topic's Gateway Post. Stocks, Bonds & Politics: Advantages and Disadvantages of Equity Preferred Floating Rate Securities
5. GOLD: I have not bought a gold mining stock in years and decided earlier this week to start nibbling on a few of them, just in case my "gut" feeling about gold prices this year proves prescient. As I noted in my last post, there is at least a meaningful possibility that Trump will be a major force in world economic instability.
Everyone guesses about the direction of gold and silver prices. Few will admit that their serious articles predicting the future directional change in price, based on charts, Fibonacci sequences or some macro issue, are no better than a coin flip-maybe even worse when their successful predictions are measured against the wrong way ones.
I flipped my current magic coin, which has not yet been fired, and called Heads for gold moving up in price this year. The coin hit the ceiling and bounced on the floor, and Heads was the verdict. I do have some reasons that support that coin flip, so I am not being entirely flippant here.
I am certainly no expert on picking mining stocks, preferring bullion ownership. Miners consume vast amounts of cash in production costs and do not shine much when reporting profits and losses. They are operationally levered to the price of gold and will generally go up or down significantly more than gold's price. Looking at the Volatile Relationship Between Gold and Gold Miners - TheStreet
GLD rose in price yesterday: GLD $115.85 1.64 1.44% : SPDR Gold Trust (1/17/17 close)
A. Bought 100 Tahoe Resources at C$11.93 and Another 100 at USD$9.03
Toronto Quote: Tahoe Resources Inc. (THO:TOR)
NYSE Quote: Tahoe Resources Inc. (TAHO:NYSE)
I bought the Canadian listed shares last Monday when the U.S. stock exchange was closed and then added 100 of the NYSE listed shares yesterday.
 |
| Toronto Listed Shares: Bought 100 at C$11.93 (C$1 commission) |
Tahoe Resources Reports 2016 Exploration Results
Summary of Results 2016 Third Quarter
2016-Q3-MDA.pdf
The information in the preceding snapshots needs no further exposition.
B. Bought 50 Goldcorp at C$19.23:
Toronto Quote: Goldcorp Inc. (G:TOR)
NYSE Quote: Goldcorp Inc. (GG:NYSE)
Goldcorp currently has a four star rating from Morningstar and a fair value estimate of USD$19.
Website: Goldcorp Inc. - Home
Financial and Operating Results:
There were huge impairment charges taken in 2014 and 2015 that are reflected in the preceding snapshot. Most of the 2014 impairment charge related to the Cerro Negro mine in Argentina.
Goldcorp 2014 Annual Report at page 21l.pdf
The 2015 impairment charge was related to several mines and was based on changes in forecasts for long term commodity prices:
2015 Annual Report at page 6.pdf
Those impairments can change based on those long term price forecasts.
MINE Results 2016 3rd Quarter
Financials-Q3-2016_FINAL.pdf
Goldcorp has been paying recently a nominal quarterly dividend: Dividends
Goldcorp Announces Sale of Los Filos Mine ("Goldcorp will receive estimated consideration of $438 million, consisting of $279 million in cash (subject to certain closing adjustments), $71 million in Leagold common shares, and retain certain tax receivables of approximately $88 million. The common shares issued to Goldcorp as consideration are expected to represent approximately 30% of the issued and outstanding shares of Leagold following the closing of the Transaction. By closing of the Transaction, Goldcorp expects to recognize a reversal of a 2015 impairment in mining interests at Los Filos of approximately $30 to $60 million on a pre-tax basis.")
I may buy a Canadian ETF that owns gold stocks to soak up some of my CADs that are building back up after selling several Canadian reset ETFs.
iShares S&P/TSX Global Gold Index ETF | XGD (expense ratio .61%)
Ishares Canada has two gold bullion ETFs:
Hedged to the Canadian Dollar: iShares Gold Bullion ETF | CGL | COMMON HEDGE
Unhedged to the Canadian Dollar: iShares Gold Bullion ETF | CGL.C | COMMON (expense ratio .5%).
GLD has a .4% expense ratio.
Disclaimer: I am not a financial advisor but simply an individual investor who has been managing my own money since I was a teenager. In this post, I am acting solely as a financial journalist focusing on my own investments. The information contained in this post is not intended to be a complete description or summary of all available data relevant to making an investment decision. Instead, I am merely expressing some of the reasons underlying the purchase or sell of securities. Nothing in this post is intended to constitute investment or legal advice or a recommendation to buy or to sell. All investors need to perform their own due diligence before making any financial decision which requires at a minimum reading original source material available at the SEC and elsewhere. A failure to perform due diligence only increases what I call "error creep". Each investor needs to assess a potential investment taking into account their personal risk tolerances, goals and situational risks. I can only make that kind of assessment for myself and family members.
